JS107 not checked
NingBo Junyan Hongshi Biosciences Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JS107: 2 mg/kg on day 1 Q3W; Toripalimab (T): 240 mg on day 1 Q3W. Capecitabine (C): 750 mg/m² BID Day1-Day14, Q3W,Oxaliplatin 100mg/m² on Day1 Q3W, Maximum of 6 cycles.”In the company’s words, NCT07584135 on ClinicalTrials.gov
- Tested for
- Gastric Adenocarcinoma
- Main trialPhase 3
- “This study is a multicenter, randomized, open-label, controlled Phase III clinical trial aimed at evaluating the efficacy and safety of JS107 combined with toripalimab XELOX versus sintilimab combined with XELOX as first-line treatment for patients with advanced G/GEJ adenocarcinoma. The research subjects were patients with unresectable locally advanced, recurrent or metastatic G/GEJ adenocarcinoma who were CLDN18.2-positive and HER2-negative and had not received systemic treatment before (except for neoadjuvant/adjuvant therapy that occurred more than 6 months after disease…”In the company’s words, NCT07584135 on ClinicalTrials.gov
Other drugs for Gastric Adenocarcinoma
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up1
- 31 Jan 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Jan 2029 | JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026